Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

EPS consensus $2.95. The company expects to deliver comparable currency neutral EPS (non-GAAP) growth of 8% to 10%. Sees FY25 organic ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Strong Operating Cash Flow and Reduction in Debt; Positioned to Pivot to Growth in Back HalfExploring Strategic Options for Personal Care ...

Palantir's growth is of extremely high quality, showcasing accelerating growth. Click here to read why I keep a Hold rating ...

Q4 2024 Management View CEO Deanna Strable highlighted achieving 2024 EPS growth of 11%, within the guided range of 9% to 12%, and a 16% year-over-year EPS increase in Q4. The company's ROE improved ...

With cyber threats on the rise, the cloud security market is growing rapidly. Investors looking to capitalize on this trend ...

Disney reported a double beat with better-than-expected Q1 results, despite a decline in Disney+ subscriptions. Check out why ...

Coca-Cola (KO) will likely continue delivering mid-single-digit organic revenue growth this year and outperforming peers despite a challenging earnings backdrop, UBS Securities said Monday. While Coca ...

The Indian stock market is crashing, yet some stocks defy gravity with sky-high P/E ratios. Are they future growth bets or ...

Church & Dwight Co., Inc. (NYSE: CHD) today announced the Company exceeded its outlook with stronger than expected sales growth. Full year 2024 net sales increased 4.1% to $6,107.1 million, ahead of ...

(RTTNews) - Kimberly-Clark Corporation (KMB) said, for 2025, the company expects mid-to-high single-digit constant-currency adjusted EPS growth. The company also projects high single-digit ...